Papillary Thyroid Cancer - Pipeline Review, H2 2016

  • ID: 3946414
  • Drug Pipelines
  • 72 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Ignyta, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Vaccinex, Inc.
  • MORE
Papillary Thyroid Cancer - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Papillary Thyroid Cancer - Pipeline Review, H2 2016, provides an overview of the Papillary Thyroid Cancer (Oncology) pipeline landscape.

Papillary thyroid cancer, also known as papillary thyroid carcinoma, is the most common form of thyroid cancer. Symptoms include throat pain, difficulty swallowing or breathing and hoarse voice. Risk factors for papillary thyroid cancer include radiation exposure and a family history of thyroid cancer. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Papillary Thyroid Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Papillary Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Papillary Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Papillary Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 2 and 2 respectively for Papillary Thyroid Cancer.

Papillary Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Papillary Thyroid Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Papillary Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Papillary Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Papillary Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Papillary Thyroid Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Papillary Thyroid Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Papillary Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ignyta, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Vaccinex, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Papillary Thyroid Cancer Overview

Therapeutics Development

Pipeline Products for Papillary Thyroid Cancer - Overview

Papillary Thyroid Cancer - Therapeutics under Development by Companies

Papillary Thyroid Cancer - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Papillary Thyroid Cancer - Products under Development by Companies

Papillary Thyroid Cancer - Companies Involved in Therapeutics Development

Blueprint Medicines Corporation

Daiichi Sankyo Company, Limited

Ignyta, Inc.

Novartis AG

Pfizer Inc.

Synactix Pharmaceuticals, Inc.

Vaccinex, Inc.

Papillary Thyroid Cancer - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

BLU-667 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dabrafenib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-7486 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-8394 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXDX-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VX-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Papillary Thyroid Cancer - Dormant Projects

Papillary Thyroid Cancer - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Papillary Thyroid Cancer, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Papillary Thyroid Cancer - Pipeline by Blueprint Medicines Corporation, H2 2016

Papillary Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016

Papillary Thyroid Cancer - Pipeline by Ignyta, Inc., H2 2016

Papillary Thyroid Cancer - Pipeline by Novartis AG, H2 2016

Papillary Thyroid Cancer - Pipeline by Pfizer Inc., H2 2016

Papillary Thyroid Cancer - Pipeline by Synactix Pharmaceuticals, Inc., H2 2016

Papillary Thyroid Cancer - Pipeline by Vaccinex, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Papillary Thyroid Cancer - Dormant Projects, H2 2016

Papillary Thyroid Cancer - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Papillary Thyroid Cancer, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Blueprint Medicines Corporation
Daiichi Sankyo Company, Limited
Ignyta, Inc.
Novartis AG
Pfizer Inc.
Synactix Pharmaceuticals, Inc.
Vaccinex, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll